Cargando…

The rediscovery of HepG2 cells for prediction of drug induced liver injury (DILI)

Detalles Bibliográficos
Autor principal:	Ghallab, Ahmed
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Leibniz Research Centre for Working Environment and Human Factors 2014
Materias:	Editorial Material
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4464501/ https://www.ncbi.nlm.nih.gov/pubmed/26417344

Ejemplares similares

Human non-parenchymal liver cells for co-cultivation systems
por: Ghallab, Ahmed
Publicado: (2014)

Highlight report: Blueprint for stem cell differentiation into liver cells
por: Ghallab, Ahmed
Publicado: (2015)

Clinical management of patients with drug‐induced liver injury (DILI)
por: Björnsson, Einar S.
Publicado: (2021)

Prediction and mechanistic analysis of drug-induced liver injury (DILI) based on chemical structure
por: Liu, Anika, et al.
Publicado: (2021)

Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
por: Stephens, Camilla, et al.
Publicado: (2012)

Metabolomic analysis to discriminate drug-induced liver injury (DILI) phenotypes
por: Quintás, Guillermo, et al.
Publicado: (2021)

The Potential Role of Metabolomics in Drug-Induced Liver Injury (DILI) Assessment
por: Moreno-Torres, Marta, et al.
Publicado: (2022)

Highlight report: New methods for quantification of bile canalicular dynamics
por: Ghallab, Ahmed
Publicado: (2015)

Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015)

Systems Toxicology
por: Ghallab, Ahmed
Publicado: (2015)

Highlight report: Role of the circadian clock system in breast cancer
por: Ghallab, Ahmed
Publicado: (2015)

Highlight report: Metabolomics in hepatotoxicity testing
por: Ghallab, Ahmed
Publicado: (2017)

Highlight report: Monitoring cytochrome P450 activities in living hepatocytes
por: Ghallab, Ahmed
Publicado: (2017)

Highlight report: Necrosis-apoptosis conundrum of hepatocytes: mode of hepatocyte death after acetaminophen intoxication
por: Ghallab, Ahmed
Publicado: (2018)

Editor’s choice 2019: Oxidative stress and antineoplastic agents
por: Ghallab, Ahmed
Publicado: (2020)

Editor’s choice 2018: Non-coding RNAs in hepatocellular cancer
por: Ghallab, Ahmed
Publicado: (2020)

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction
por: Segovia-Zafra, Antonio, et al.
Publicado: (2021)

Models of Drug Induced Liver Injury (DILI) – Current Issues and Future Perspectives
por: Kuna, Lucija, et al.
Publicado: (2018)

Overview of Causality Assessment for Drug-Induced Liver Injury (DILI) in Clinical Trials
por: Hey-Hadavi, Juliana, et al.
Publicado: (2021)

Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues
por: Teschke, Rolf, et al.
Publicado: (2021)

Comment: Drug-Induced Liver Injury (DILI) With Micafungin: The Importance of Causality Assessment
por: Danjuma, Mohammed, et al.
Publicado: (2020)

Role of Hepatocyte Transporters in Drug-Induced Liver Injury (DILI)—In Vitro Testing
por: Tátrai, Péter, et al.
Publicado: (2022)

Machine-Learning Prediction of Oral Drug-Induced Liver Injury (DILI) via Multiple Features and Endpoints
por: Liu, Xiaobin, et al.
Publicado: (2020)

The generation of HepG2 transmitochondrial cybrids to reveal the role of mitochondrial genotype in idiosyncratic drug-induced liver injury
por: Ball, Amy Louise, et al.
Publicado: (2023)

Guideline review: EASL clinical practice guidelines: drug-induced liver injury (DILI)
por: Brennan, Paul N, et al.
Publicado: (2021)

DILI( C ): An AI-Based Classifier to Search for Drug-Induced Liver Injury Literature
por: Rathee, Sanjay, et al.
Publicado: (2022)

Drug-induced mitochondrial impairment in liver cells
por: Stöber, Regina
Publicado: (2015)

Infliximab (IFX)-Biosimilar Induced Drug-Induced Liver Injury (DILI): A Case Report
por: Zachou, Maria, et al.
Publicado: (2022)

The idiosyncratic drug-induced gene expression changes in HepG2 cells
por: Jiang, J., et al.
Publicado: (2017)

The evolution of strategies to minimise the risk of human drug-induced liver injury (DILI) in drug discovery and development
por: Walker, Paul A., et al.
Publicado: (2020)

HepG2-Based Designer Cells with Heat-Inducible Enhanced Liver Functions
por: Kitano, Hiroyuki, et al.
Publicado: (2022)

Nevirapine induced mitochondrial dysfunction in HepG2 cells
por: Paemanee, Atchara, et al.
Publicado: (2017)

Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells
por: Ramirez, Tzutzuy, et al.
Publicado: (2017)

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry
por: Björnsson, Einar S., et al.
Publicado: (2022)

Oxidative Stress in Drug-Induced Liver Injury (DILI): From Mechanisms to Biomarkers for Use in Clinical Practice
por: Villanueva-Paz, Marina, et al.
Publicado: (2021)

The Promise of AI for DILI Prediction
por: Vall, Andreu, et al.
Publicado: (2021)

Epigenetic Modifications of the Liver Tumor Cell Line HepG2 Increase Their Drug Metabolic Capacity
por: Ruoß, Marc, et al.
Publicado: (2019)

Toxicity Assessment of Octachlorostyrene in Human Liver Carcinoma (HepG2) Cells
por: Ren, Guofa, et al.
Publicado: (2022)

Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery
por: Peta, Valentina, et al.
Publicado: (2017)

2409. Drug-Induced Liver Injury (DILI) in a National Cohort of Hospitalized Patients Treated With Aztreonam and Ceftazidime
por: Saade, Elie, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ab3dr4po138n2qiti5bjie5hgn